Chemotherapy increases the overall survival in
colorectal cancer (CRC) patients.
5-Fluorouracil (5-FU) remains as a
drug of first choice in CRC
therapy over the last four decades. However, only 10-15% of patients with advanced CRC respond positively to
5-FU monotherapy. Therefore, new strategies to enhance the
5-FU effectiveness, overcome the
tumor cell resistance and decrease the unspecific toxicity are critically needed.
Urolithin A (Uro-A) is the main metabolite produced by the human gut microbiota from the dietary
polyphenol ellagic acid. Uro-A targets the colonic mucosa of CRC patients, and preclinical studies have shown the anti-inflammatory and
cancer chemopreventive activities of this metabolite. We evaluated here whether Uro-A, at concentrations achievable in the human colorectum, could sensitize
colon cancer cells to
5-FU and 5'DFUR (a
pro-drug intermediate of 5-FU). We found that both
5-FU and 5'DFUR arrested the cell cycle at the S phase by regulating
cyclins A and B1 in the human
colon cancer cells Caco-2, SW-480 and HT-29, and also triggered apoptosis through the activation of
caspases 8 and 9. Co-treatments with Uro-A decreased IC50 values for both
5-FU and 5'DFUR and additionally arrested the cell cycle at the G2/M phase together with a slight increase in
caspases 8 and 9 activation. Overall, we show that Uro-A potentiated the effects of both
5-FU and 5'DFUR on
colon cancer cells. This suggests the need for lower
5-FU doses to achieve similar effects, which could reduce possible adverse effects. Further in vivo investigations are warranted to explore the possible role of Uro-A as a
chemotherapy adjuvant.